Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1) [0.03%]
奥拉帕利联合卡铂和/或紫杉醇治疗晚期复发性卵巢癌、输卵管癌或原发性腹膜癌患者的I期临床试验（第一部分）
Ruud van der Noll,Agnes Jager,Joo Ern Ang et al.
Ruud van der Noll et al.
Background The PARP inhibitor olaparib has shown acceptable toxicity at doses of up to 400 mg twice daily (bid; capsule formulation) with encouraging signs of antitumor activity. Based on its mode of action, olaparib may sensitize tumor cel...
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma [0.03%]
一种名为everolimus的mTOR抑制剂与泛组蛋白脱乙酰酶抑制剂panobinostat联合治疗晚期透明细胞肾癌的I期临床研究
Anthony Wood,Saby George,Nabil Adra et al.
Anthony Wood et al.
Background Preclinical studies suggested synergistic anti-tumor activity when pairing mTOR inhibitors with histone deacetylase (HDAC) inhibitors. We completed a phase I, dose-finding trial for the mTOR inhibitor everolimus combined with the...
Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma [0.03%]
阿帕替尼联合S-1治疗晚期食管鳞癌的临床疗效及安全性分析
Jian Zhao,Junmei Lei,Junyan Yu et al.
Jian Zhao et al.
Background Esophageal cancer is a very common malignant tumor in China, especially esophageal squamous cell carcinoma (ESCC), but there is currently no effective treatment for patients after first-line chemotherapy failure. Apatinib has sho...
Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach [0.03%]
奥拉帕尼在卵巢癌中的应用——一种新的合成致死性治疗方法
Stergios Boussios,Peeter Karihtala,Michele Moschetta et al.
Stergios Boussios et al.
Epithelial ovarian cancer (EOC) accounts for nearly 90% of all ovarian malignancies. The standard therapeutic strategy includes cytoreductive surgery and neo (adjuvant) platinum-based chemotherapy. Relapse of advanced high grade serous ovar...
Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells [0.03%]
裸反义寡核苷酸高效抑制BCR-ABL阳性白血病细胞
Toshimi Hoshiko,Yasushi Kubota,Takuya Akisawa et al.
Toshimi Hoshiko et al.
Oligonucleotide-based gene silencing, using molecules such as antisense oligonucleotides (ASOs), small interfering RNA, and aptamers, is widely studied. Another approach uses DNA/RNA heteroduplex oligonucleotides (HDOs). Here, we developed ...
Prolonged response to 177Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor [0.03%]
长效177Lu-DOTATATE治疗顽固性胸腺神经内分泌肿瘤骨髓浸润的疗效分析
Anne Ségolène Cottereau,Léopoldine Bricaire,Jennifer Arrondeau et al.
Anne Ségolène Cottereau et al.
Thymic neuro endocrine tumor (tNET) are extremely rare malignancies with poor prognosis, requiring investigation of novel therapeutic approaches. 177Lu-DOTATATE is a successful systemic treatment modality in patients with metastatic gastroe...
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2) [0.03%]
奥拉帕利联合卡铂和紫杉醇治疗方案的研究（第二部分）
Ruud van der Noll,Agnes Jager,Joo Ern Ang et al.
Ruud van der Noll et al.
Background In the first part of this extensive phase I study (NCT00516724), continuous olaparib twice daily (bid) with carboplatin and/or paclitaxel resulted in myelosuppression and dose modifications. Here, we report the safety, tolerabili...
Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients [0.03%]
作为复发或晚期宫颈癌二线治疗的新血管生成酪氨酸激酶抑制剂阿帕替尼的II期临床研究
Linlin Zhang,Liang Chen,Hao Yu
Linlin Zhang
This study was designed to evaluate the efficacy and safety of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment in recurrent or advanced cervical cancer patients. Twenty patients who failed ...
Impact of L-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor [0.03%]
左卡尼丁对胃肠间质瘤伊马替尼相关性肌肉痉挛的影响
Heejung Chae,Min-Hee Ryu,Jungeun Ma et al.
Heejung Chae et al.
Introduction Muscle cramps constitute one of the leading adverse events of imatinib, the standard first-line treatment for advanced gastrointestinal stromal tumor (GIST). This study aims to assess the impact of L-carnitine on relieving cram...
Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3 [0.03%]
新型JAK1和JAK2抑制剂氢溴酸艾托帕沙通过选择性诱导STAT3信号通路异常的癌细胞凋亡而发挥抗肿瘤作用的研究与评价
Jingjie Sun,Yuping Du,Xinxin Zhang et al.
Jingjie Sun et al.
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway plays a vital role in immunity, cell division, cell death and tumor formation. Disrupted JAK-STAT signaling may lead to various diseases, especia...